Key Takeaways
- Former US President Joe Biden (82) has commenced radiation therapy and hormone treatment for an aggressive form of prostate cancer.
- The cancer, diagnosed in May, is characterized by a Gleason score of 9 (Grade Group 5) and has metastasized to the bone, though it is described as hormone-sensitive.
- The radiation treatment is anticipated to span five weeks, marking a new phase in his ongoing care.
- Biden is reportedly "doing well" and responding to the treatment, having already been on hormone medication in pill form.
Former US President Joe Biden, 82, has begun radiation therapy and hormone treatment as part of his care plan for an aggressive form of prostate cancer. The treatment commenced around October 11, 2025, following a diagnosis in May of the same year. A spokesperson confirmed that the former president is currently undergoing both radiation and hormone therapy.
The prostate cancer was diagnosed in May 2025 and was identified as an aggressive form with a Gleason score of 9 (Grade Group 5), indicating it had spread to his bones. Despite its aggressive nature, the cancer is considered hormone-sensitive, which allows for effective management. Biden had previously stated that he was optimistic about his prognosis, expecting to "beat this" as it had not penetrated any organs, and his bones were strong.
The radiation treatment is expected to last for five weeks, representing a new stage in his overall care. Prior to this, Biden had already been taking hormone medication in pill form. Sources familiar with his condition indicate that the former president is "doing well" and responding positively to the treatment.
This health update follows another recent medical procedure; in September 2025, Biden underwent Mohs surgery to remove skin cancer lesions. He had also had a basal cell carcinoma removed from his chest in 2023 while still in office.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.